Deals In Depth: June 2022
Executive Summary
Six $1B+ alliances were penned in June. Topping the list was a potential $4.26M deal between Immatics and Bristol Myers Squibb for the development of multiple allogeneic off-the-shelf TCR-T and/or CAR-T programs. The companies seek to develop two BMS-owned programs and both firms will have an option to develop up to four additional programs each. The programs will utilize Immatics’ ACTallo proprietary allogeneic gamma delta T cell-derived adoptive cell therapy platform. BMS contributes its suite of next-generation technologies as well as its oncology drug development expertise. Bristol Myers Squibb was also involved in the top June M&A by deal value. The company entered into an agreement to acquire Turning Point Therapeutics in an all-cash transaction with an equity value of $4.1B. Founded in 2013 as TP Therapeutics, Turning Point has advanced a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis. Its lead asset, repotrectinib, is a next-generation, potential best-in-class tyrosine kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer and other advanced solid tumors. Repotrectinib has been granted three Breakthrough Therapy designations from the US FDA. BMS expects the therapy to be approved in H2 2023 and become a new standard of care for patients with ROS1-positive NSCLC in the first-line setting. Turning Point also has several other clinical-stage oncology candidates in addition to multiple discovery programs. Financing reached $5.2bn in biopharma, $498m in device, and $311m in diagnostics.
Pharma Intelligence